3.3. Secondary Endpoints
Secondary endpoint evaluations were performed for the changes in E2 levels, FSH levels, total occurrences of daytime and nighttime flushes, and total scores of daytime and nighttime flushes from baseline to 12 days after treatment. The analysis did not show any statistically significant differences between the treatment group and the control group for all evaluation variables (Therefore, when comparing Unicenta, the investigational drug, with the control drug Melsmon, it is demonstrated that Unicenta is non-inferior in terms of the menopausal symptom score (Kupperman index). Additionally, there were no statistically significant differences in hormone levels (estradiol, FSH) or in the evaluation of facial flushes.